OncoCyte (OCX)
(Delayed Data from NSDQ)
$3.24 USD
+0.07 (2.05%)
Updated Jul 23, 2024 03:59 PM ET
After-Market: $3.22 -0.02 (-0.46%) 6:16 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
OCX 3.24 +0.07(2.05%)
Will OCX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for OCX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OCX
CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates
Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates
OCX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Elevance Health (ELV) Tops Q1 Earnings and Revenue Estimates
3 Medical Services Stocks to Buy Amid Industry Challenges
Life Time Group Holdings, Inc. (LTH) Tops Q4 Earnings and Revenue Estimates
Other News for OCX
MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in "Take Advantage of the Moment" Episode
Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move
Oncocyte Appoints Andrea James as Chief Financial Officer
OncoCyte Announces Andrea James as New CFO and Principal Officer
OncoCyte appoints CFO